Advances in the pathogenesis and treatment of polycystic kidney disease

Vishal Patel, Renuka Chowdhury, Peter Igarashi

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Purpose of review Polycystic kidney disease (PKD) is the most common genetic cause of chronic renal failure. Mouse models of PKD, especially those with mutations in genes that are orthologous to human disease genes, have provided insights into the pathogenesis of cyst formation and advanced the preclinical testing of new drugs. Recent findings PKD is a ciliopathy that arises from abnormalities in the primary cilium, a sensory organelle present on the surface of most cells. The primary cilium is required for the maintenance of planar cell polarity, which regulates tubular diameter. Acute kidney injury stimulates cell proliferation and promotes cyst formation in a mouse model of PKD. Studies of signaling pathways that are perturbed in PKD have identified new potential therapeutic targets. Drugs that have shown beneficial effects in orthologous animal models of PKD include tolvaptan, octreotide, src inhibitors, CFTR inhibitors, pioglitazone, etanercept, and triptolide. Summary Abnormalities in the primary cilium perturb signaling pathways that regulate renal epithelial cell growth and differentiation and lead to the formation of kidney cysts. Acute kidney injury promotes cyst formation and may underlie the variability in disease progression that is observed in affected individuals. Several promising new therapeutic agents that have been validated in orthologous animal models have entered clinical trials in humans.

Original languageEnglish (US)
Pages (from-to)99-106
Number of pages8
JournalCurrent Opinion in Nephrology and Hypertension
Volume18
Issue number2
DOIs
StatePublished - Mar 2009

Fingerprint

Polycystic Kidney Diseases
Cysts
Cilia
pioglitazone
Acute Kidney Injury
Animal Models
Kidney
Cell Polarity
Octreotide
Pharmaceutical Preparations
Organelles
Genes
Chronic Kidney Failure
Disease Progression
Cell Differentiation
Epithelial Cells
Maintenance
Cell Proliferation
Clinical Trials
Mutation

Keywords

  • Acute kidney injury
  • Cilia
  • Planar cell polarity
  • Polycystic kidney disease
  • Rapamycin
  • Tolvaptan

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Advances in the pathogenesis and treatment of polycystic kidney disease. / Patel, Vishal; Chowdhury, Renuka; Igarashi, Peter.

In: Current Opinion in Nephrology and Hypertension, Vol. 18, No. 2, 03.2009, p. 99-106.

Research output: Contribution to journalArticle

@article{d97ed6506dfa42dda044ae3b8385fa5f,
title = "Advances in the pathogenesis and treatment of polycystic kidney disease",
abstract = "Purpose of review Polycystic kidney disease (PKD) is the most common genetic cause of chronic renal failure. Mouse models of PKD, especially those with mutations in genes that are orthologous to human disease genes, have provided insights into the pathogenesis of cyst formation and advanced the preclinical testing of new drugs. Recent findings PKD is a ciliopathy that arises from abnormalities in the primary cilium, a sensory organelle present on the surface of most cells. The primary cilium is required for the maintenance of planar cell polarity, which regulates tubular diameter. Acute kidney injury stimulates cell proliferation and promotes cyst formation in a mouse model of PKD. Studies of signaling pathways that are perturbed in PKD have identified new potential therapeutic targets. Drugs that have shown beneficial effects in orthologous animal models of PKD include tolvaptan, octreotide, src inhibitors, CFTR inhibitors, pioglitazone, etanercept, and triptolide. Summary Abnormalities in the primary cilium perturb signaling pathways that regulate renal epithelial cell growth and differentiation and lead to the formation of kidney cysts. Acute kidney injury promotes cyst formation and may underlie the variability in disease progression that is observed in affected individuals. Several promising new therapeutic agents that have been validated in orthologous animal models have entered clinical trials in humans.",
keywords = "Acute kidney injury, Cilia, Planar cell polarity, Polycystic kidney disease, Rapamycin, Tolvaptan",
author = "Vishal Patel and Renuka Chowdhury and Peter Igarashi",
year = "2009",
month = "3",
doi = "10.1097/MNH.0b013e3283262ab0",
language = "English (US)",
volume = "18",
pages = "99--106",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Advances in the pathogenesis and treatment of polycystic kidney disease

AU - Patel, Vishal

AU - Chowdhury, Renuka

AU - Igarashi, Peter

PY - 2009/3

Y1 - 2009/3

N2 - Purpose of review Polycystic kidney disease (PKD) is the most common genetic cause of chronic renal failure. Mouse models of PKD, especially those with mutations in genes that are orthologous to human disease genes, have provided insights into the pathogenesis of cyst formation and advanced the preclinical testing of new drugs. Recent findings PKD is a ciliopathy that arises from abnormalities in the primary cilium, a sensory organelle present on the surface of most cells. The primary cilium is required for the maintenance of planar cell polarity, which regulates tubular diameter. Acute kidney injury stimulates cell proliferation and promotes cyst formation in a mouse model of PKD. Studies of signaling pathways that are perturbed in PKD have identified new potential therapeutic targets. Drugs that have shown beneficial effects in orthologous animal models of PKD include tolvaptan, octreotide, src inhibitors, CFTR inhibitors, pioglitazone, etanercept, and triptolide. Summary Abnormalities in the primary cilium perturb signaling pathways that regulate renal epithelial cell growth and differentiation and lead to the formation of kidney cysts. Acute kidney injury promotes cyst formation and may underlie the variability in disease progression that is observed in affected individuals. Several promising new therapeutic agents that have been validated in orthologous animal models have entered clinical trials in humans.

AB - Purpose of review Polycystic kidney disease (PKD) is the most common genetic cause of chronic renal failure. Mouse models of PKD, especially those with mutations in genes that are orthologous to human disease genes, have provided insights into the pathogenesis of cyst formation and advanced the preclinical testing of new drugs. Recent findings PKD is a ciliopathy that arises from abnormalities in the primary cilium, a sensory organelle present on the surface of most cells. The primary cilium is required for the maintenance of planar cell polarity, which regulates tubular diameter. Acute kidney injury stimulates cell proliferation and promotes cyst formation in a mouse model of PKD. Studies of signaling pathways that are perturbed in PKD have identified new potential therapeutic targets. Drugs that have shown beneficial effects in orthologous animal models of PKD include tolvaptan, octreotide, src inhibitors, CFTR inhibitors, pioglitazone, etanercept, and triptolide. Summary Abnormalities in the primary cilium perturb signaling pathways that regulate renal epithelial cell growth and differentiation and lead to the formation of kidney cysts. Acute kidney injury promotes cyst formation and may underlie the variability in disease progression that is observed in affected individuals. Several promising new therapeutic agents that have been validated in orthologous animal models have entered clinical trials in humans.

KW - Acute kidney injury

KW - Cilia

KW - Planar cell polarity

KW - Polycystic kidney disease

KW - Rapamycin

KW - Tolvaptan

UR - http://www.scopus.com/inward/record.url?scp=63849273195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849273195&partnerID=8YFLogxK

U2 - 10.1097/MNH.0b013e3283262ab0

DO - 10.1097/MNH.0b013e3283262ab0

M3 - Article

C2 - 19430332

AN - SCOPUS:63849273195

VL - 18

SP - 99

EP - 106

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 2

ER -